The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -5.59 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2023, as PALVELLA THERAPEUTICS, INC. reports it. History and quarterly detail are in the app.
- Pfizer$15.1M
- Genentech$12.7M
- Astra Zeneca AB$8.4M
- Les Laboratoires Servier And Institut De Recherches Internationales Servier$4.1M
- Boston Pharmaceuticals$2.5M
Leadership changes
From PALVELLA THERAPEUTICS, INC.'s own filings, the day they're filed.
- Shane Olwill · Chief Development Officer · departureeff. 2024-10-31
- John Doux · director · appointment
- Stephen Yoder · Chief Executive Officer · departure
Latest filings
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-15
- 8-K · Company announcement2026-05-13
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about PALVELLA THERAPEUTICS, INC., every answer cited🔒
- The Intelligence Brief — added when PALVELLA THERAPEUTICS, INC.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.